{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T06:28:30Z","timestamp":1758349710719,"version":"3.44.0"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_almed-2025-0110_abs_001\">\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The <jats:italic>BRAF V600E<\/jats:italic> mutation is one of the most relevant genetic mutations in precision oncology. This variation is commonly found in several types of tumors, including melanoma, colorectal cancer, and thyroid cancer, to name a few. Liquid biopsy has emerged as a minimally-invasive screening option for this mutation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2025-0110_abs_002\">\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>This review examines the molecular biology of the <jats:italic>BRAF V600E<\/jats:italic> mutation, its role in tumor progression, and its utility in the diagnosis, prognosis and treatment of specific types of tumors. In addition, the focus is also placed on liquid biopsy-based screening options and their advantages over solid biopsy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2025-0110_abs_003\">\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Detection of this mutation through liquid biopsy offers a less invasive alternative to conventional tissue biopsies, with potential utility in guiding treatment adjustments and monitoring therapeutic response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2025-0110_abs_004\">\n                  <jats:title>Outlook<\/jats:title>\n                  <jats:p>The use of liquid biopsy for the detection of <jats:italic>BRAF V600E<\/jats:italic> is expected to widespread in clinical practice, leading to the optimization of disease monitoring and personalized treatments for cancer patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/almed-2025-0110","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T06:56:26Z","timestamp":1755327386000},"page":"298-305","source":"Crossref","is-referenced-by-count":0,"title":["<i>BRAF V600E<\/i> liquid biopsy-based detection in precision oncology"],"prefix":"10.1515","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1247-269X","authenticated-orcid":false,"given":"Gabriela R.","family":"Mendeluk","sequence":"first","affiliation":[{"name":"Departamento de Bioqu\u00edmica Cl\u00ednica , Hospital de Cl\u00ednicas\u201dJos\u00e9 de San Mart\u00edn\u201d. Universidad de Buenos Aires. Instituto de Fisiopatolog\u00eda y Bioqu\u00edmica Cl\u00ednica- INFIBIOC , C.A.B.A , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4653-5235","authenticated-orcid":false,"given":"Ver\u00f3nica A.","family":"Alonso","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry , Hospital de Cl\u00ednicas\u201dJos\u00e9 de San Mart\u00edn\u201d. University of Buenos Aires. Institute of Physiopathology and Clinical Biochemistry- INFIBIOC , C.A.B.A , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"2025091905582874423_j_almed-2025-0110_ref_001","doi-asserted-by":"crossref","unstructured":"Tsimberido, AM, Fountzilas, E, Nikanjam, M, Kurzrock, R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev 2020;86:102019. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102019.","DOI":"10.1016\/j.ctrv.2020.102019"},{"key":"2025091905582874423_j_almed-2025-0110_ref_002","doi-asserted-by":"crossref","unstructured":"Shin, SH, Bode, AM, Dong, Z. Addressing the challenges of applying precision oncology. npj Precis Oncol 2017;1:28. https:\/\/doi.org\/10.1038\/s41698-017-0032-z.","DOI":"10.1038\/s41698-017-0032-z"},{"key":"2025091905582874423_j_almed-2025-0110_ref_003","doi-asserted-by":"crossref","unstructured":"Ritterhouse, LL, Barletta, JA. BRAF V600E mutation-specific antibody: a review. Semin Diagn Pathol 2015;32:400\u20138. https:\/\/doi.org\/10.1053\/j.semdp.2015.02.010. Epub 2015 Feb 7. PMID: 25744437.","DOI":"10.1053\/j.semdp.2015.02.010"},{"key":"2025091905582874423_j_almed-2025-0110_ref_004","doi-asserted-by":"crossref","unstructured":"Wang, W, Lian, B, Xu, C, Wang, Q, Li, Z, Zheng, N, et al.. Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations. Innovation 2024;5:100661. https:\/\/doi.org\/10.1016\/j.xinn.2024.100661. PMID: 39529955; PMCID: PMC11551471.","DOI":"10.1016\/j.xinn.2024.100661"},{"key":"2025091905582874423_j_almed-2025-0110_ref_005","doi-asserted-by":"crossref","unstructured":"Johnson, DB, Zhao, F, Noel, M, Riely, GJ, Mitchell, EP, Wright, JJ, et al.. Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131). Clin Cancer Res 2020;26:1812\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3443. Epub 2020 Jan 10. PMID: 31924734; PMCID: PMC7165046. Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, et\u00a0al. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clin Cancer Res. 2020 Apr 15;26(8):1812-1819. d\u200boi: 10.1158\/1078-0432.CCR-19-3443. Epub 2020 Jan 10. PMID: 31924734; PMCID: PMC7165046.","DOI":"10.1158\/1078-0432.CCR-19-3443"},{"key":"2025091905582874423_j_almed-2025-0110_ref_006","doi-asserted-by":"crossref","unstructured":"Burjanivova, T, Malicherova, B, Grendar, M, Minarikova, E, Dusenka, R, Vanova, B, et al.. Detection of BRAF V600E mutation in melanoma patients by digital PCR of circulating DNA. Genet Test Mol Biomarkers 2019;23:241\u20135. https:\/\/doi.org\/10.1089\/gtmb.2018.0193. Epub 2019 Jan 24. PMID: 30676087.","DOI":"10.1089\/gtmb.2018.0193"},{"key":"2025091905582874423_j_almed-2025-0110_ref_007","doi-asserted-by":"crossref","unstructured":"Syeda, MM, Wiggins, JM, Corless, BC, Long, GV, Flaherty, KT, Schadendorf, D, et al.. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol 2021;22:370\u201380. Epub 2021 Feb 12. PMID: 33587894; PMCID: PMC8034833 https:\/\/doi.org\/10.1016\/S1470-2045(20)30726-9.","DOI":"10.1016\/S1470-2045(20)30726-9"},{"key":"2025091905582874423_j_almed-2025-0110_ref_008","unstructured":"Tian, J, Chen, JH, Chao, SX, Pelka, K, Giannakis, M, Hess, J, et al.. Combined PD-1, BRAF and MEK inhibition in BRAF V600E colorectal cancer: a phase 2 trial. Nat Med 2023;29:458\u201366. https:\/\/doi.org\/10.1038\/s41591-022-02181-8. Epub 2023 Jan 26. PMID: 36702949; PMCID: PMC9941044."},{"key":"2025091905582874423_j_almed-2025-0110_ref_009","doi-asserted-by":"crossref","unstructured":"Dummer, R, Hauschild, A, Santinami, M, Atkinson, V, Mandal\u00e0, M, Kirkwood, JM, et al.. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N\u00a0Engl J Med 2020;383:1139\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2005493. Epub 2020 Sep 2. PMID: 32877599.","DOI":"10.1056\/NEJMoa2005493"},{"key":"2025091905582874423_j_almed-2025-0110_ref_010","doi-asserted-by":"crossref","unstructured":"M\u00e1rquez-Rodas, I, \u00c1lvarez, A, Arance, A, Valduvieco, I, Berciano-Guerrero, M\u00c1, Delgado, R, et al.. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN\/GEM1802 phase II study). Neuro Oncol 2024;26:2074\u201383. https:\/\/doi.org\/10.1093\/neuonc\/noae116. PMID: 38946469; PMCID: PMC11534317 CLINICAL TRIAL; TRATAMIENTO.","DOI":"10.1093\/neuonc\/noae116"},{"key":"2025091905582874423_j_almed-2025-0110_ref_011","unstructured":"Atkins, MB, Lee, SJ, Chmielowski, B, Tarhini, AA, Cohen, GI, Truong, TG, et al.. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol 2023;41:186\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01763. Epub 2022 Sep 27. PMID: 36166727; PMCID: PMC9839305."},{"key":"2025091905582874423_j_almed-2025-0110_ref_012","doi-asserted-by":"crossref","unstructured":"Rashid, FA, Munkhdelger, J, Fukuoka, J, Bychkov, A. Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review. Gland Surg 2020;9:1878\u2013900. https:\/\/doi.org\/10.21037\/gs-20-430.","DOI":"10.21037\/gs-20-430"},{"key":"2025091905582874423_j_almed-2025-0110_ref_013","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez Ayala, M, Exp\u00f3sito Rodr\u00edguez, A, Bilbao Gonz\u00e1lez, A, M\u00ednguez Gabi\u00f1a, P, Guti\u00e9rrez Rodr\u00edguez, T, Rode\u00f1o Ortiz de Zarate, E, et al.. BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: should we modify our therapeutic strategy? Cir Esp (Engl Ed) 2018;96:276\u201382. https:\/\/doi.org\/10.1016\/j.ciresp.2018.02.018. English, Spanish Epub 2018 Mar 19. PMID: 29567362.","DOI":"10.1016\/j.cireng.2018.05.010"},{"key":"2025091905582874423_j_almed-2025-0110_ref_014","doi-asserted-by":"crossref","unstructured":"Busaidy, NL, Konda, B, Wei, L, Wirth, LJ, Devine, C, Daniels, GA, et al.. Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 2022;32:1184\u201392. https:\/\/doi.org\/10.1089\/thy.2022.0115. Epub 2022 Jul 5. PMID: 35658604; PMCID: PMC9595631.","DOI":"10.1089\/thy.2022.0115"},{"key":"2025091905582874423_j_almed-2025-0110_ref_015","doi-asserted-by":"crossref","unstructured":"Abdulhaleem, M, Bandargal, S, Pusztaszeri, MP, Rajab, M, Greenspoon, H, Krasner, JR, et al.. The impact of BRAF V600E mutation allele frequency on the histopathological characteristics of thyroid cancer. Cancers (Basel) 2023;16:113. https:\/\/doi.org\/10.3390\/cancers16010113. PMID: 38201541; PMCID: PMC10777954.","DOI":"10.3390\/cancers16010113"},{"key":"2025091905582874423_j_almed-2025-0110_ref_016","doi-asserted-by":"crossref","unstructured":"Subbiah, V, Kreitman, RJ, Wainberg, ZA, Cho, JY, Schellens, JHM, Soria, JC, et al.. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022;33:406\u201315. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014. Epub 2022 Jan 10. PMID: 35026411; PMCID: PMC9338780.","DOI":"10.1016\/j.annonc.2021.12.014"},{"key":"2025091905582874423_j_almed-2025-0110_ref_017","doi-asserted-by":"crossref","unstructured":"Ionescu, A, Bilteanu, L, Geicu, OI, Iordache, F, Stanca, L, Pisoschi, AM, et al.. Multivariate risk analysis of RAS, BRAF and EGFR mutations allelic frequency and coexistence as colorectal cancer predictive biomarkers. Cancers (Basel) 2022;14:2792. https:\/\/doi.org\/10.3390\/cancers14112792. PMID: 35681771; PMCID: PMC9179415.","DOI":"10.3390\/cancers14112792"},{"key":"2025091905582874423_j_almed-2025-0110_ref_018","doi-asserted-by":"crossref","unstructured":"Ciombor, KK, Strickler, JH, Bekaii-Saab, TS, Yaeger, R. BRAF-mutated advanced colorectal cancer: a rapidly changing therapeutic landscape. J\u00a0Clin Oncol 2022;40:2706\u201315. https:\/\/doi.org\/10.1200\/JCO.21.02541. Epub 2022 Jun 1. PMID: 35649231; PMCID: PMC9390817.","DOI":"10.1200\/JCO.21.02541"},{"key":"2025091905582874423_j_almed-2025-0110_ref_019","unstructured":"Ortiz, C, Dongo-Pflucker, K, Mart\u00edn-Cruz, L, Barletta Carrillo, C, Mora-Alferez, P, Arias, A. Inestabilidad de microsat\u00e9lites en pacientes con diagn\u00f3stico de c\u00e1ncer colorrectal [Microsatellite instability in patients with diagnostic of colorectal cancer]. Rev Gastroenterol Peru 2016;36:15\u201322. Spanish. PMID: 27131936."},{"key":"2025091905582874423_j_almed-2025-0110_ref_020","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, T, Shiu, KK, Kim, TW, Jensen, BV, Jensen, LH, Punt, C, et al.. KEYNOTE-177 investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N\u00a0Engl J Med 2020;383:2207\u201318. PMID: 33264544. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","DOI":"10.1056\/NEJMoa2017699"},{"key":"#cr-split#-2025091905582874423_j_almed-2025-0110_ref_021.1","doi-asserted-by":"crossref","unstructured":"Martinelli, E, Cremolini, C, Mazard, T, Vidal, J, Virchow, I, Tougeron, D, et al.. Real-world first-line treatment of patients with BRAF V600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open 2022;7:100603. https:\/\/doi.org\/10.1016\/j.esmoop.20.Epub 2022 Nov 8. PMID: 36368253","DOI":"10.1016\/j.esmoop.2022.100603"},{"key":"#cr-split#-2025091905582874423_j_almed-2025-0110_ref_021.2","doi-asserted-by":"crossref","unstructured":"PMCID: PMC9832736.Open. 2022 Dec;7(6):100603","DOI":"10.1016\/j.esmoop.2022.100603"},{"key":"2025091905582874423_j_almed-2025-0110_ref_022","doi-asserted-by":"crossref","unstructured":"Kopetz, S, Yoshino, T, Van Cutsem, E, Eng, C, Kim, TW, Wasan, HS, et al.. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med 2025;31:901. https:\/\/doi.org\/10.1038\/s41591-024-03443-3. PMID: 39863775.","DOI":"10.1038\/s41591-024-03443-3"},{"key":"2025091905582874423_j_almed-2025-0110_ref_023","unstructured":"Roviello, G, D\u2019Angelo, A, Sirico, M, Pittacolo, M, Conter, FU, Sobhani, N. Advances in anti-BRAF therapies for lung cancer. Invest New Drugs 2021;39:879\u201390. https:\/\/doi.org\/10.1007\/s10637-021-01068-8. Epub 2021 Jan 21. Erratum in: Invest New Drugs. 2021 Oct;39(5):1456. d\u200boi: 10.1007\/s10637-021-01092-8. PMID: 33474634; PMCID: PMC8068629."},{"key":"2025091905582874423_j_almed-2025-0110_ref_024","unstructured":"Xiao, P, Zhong, D. Research progress of BRAF fusion in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2023;26:782\u20138. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2023.101.28. Chinese PMID: 37989341; PMCID: PMC10663773."},{"key":"2025091905582874423_j_almed-2025-0110_ref_025","doi-asserted-by":"crossref","unstructured":"Van den Bent, MJ, Geurts, M, French, PJ, Smits, M, Capper, D, Bromberg, JEC, et al.. Primary brain tumours in adults. Lancet 2023;402:1564\u201379. Epub 2023 Sep 19. PMID: 37738997 https:\/\/doi.org\/10.1016\/S0140-6736(23)01054-1.","DOI":"10.1016\/S0140-6736(23)01054-1"},{"key":"2025091905582874423_j_almed-2025-0110_ref_026","doi-asserted-by":"crossref","unstructured":"Bouffet, E, Hansford, JR, Garr\u00e8, ML, Hara, J, Plant-Fox, A, Aerts, I, et al.. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N\u00a0Engl J Med 2023;389:1108\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2303815. PMID: 37733309.","DOI":"10.1056\/NEJMoa2303815"},{"key":"2025091905582874423_j_almed-2025-0110_ref_027","doi-asserted-by":"crossref","unstructured":"Perrone, C, Angioli, R, Luvero, D, Giannini, A, Di Donato, V, Cuccu, I, et al.. Targeting BRAF pathway in low-grade serous ovarian cancer. J\u00a0Gynecol Oncol 2024;35:e104. https:\/\/doi.org\/10.3802\/jgo.2024.35.e104. Epub 2024 May 14. PMID: 38768941; PMCID: PMC11262891.","DOI":"10.3802\/jgo.2024.35.e104"},{"key":"2025091905582874423_j_almed-2025-0110_ref_028","doi-asserted-by":"crossref","unstructured":"Subbiah, V, Kreitman, RJ, Wainberg, ZA, Gazzah, A, Lassen, U, Stein, A, et al.. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 2023;29:1103\u201312. https:\/\/doi.org\/10.1038\/s41591-023-02321-8. Epub 2023 Apr 14. PMID: 37059834; PMCID: PMC10202803.","DOI":"10.1038\/s41591-023-02321-8"},{"key":"2025091905582874423_j_almed-2025-0110_ref_029","doi-asserted-by":"crossref","unstructured":"Arechederra, M, \u00c1vila, MA, Berasain, C. La biopsia l\u00edquida en el manejo del c\u00e1ncer: una nueva herramienta revolucionaria de la medicina de precisi\u00f3n, a\u00fan con limitaciones. Adv Lab Med 2020;1:20200038. https:\/\/doi.org\/10.1515\/almed-2020-0038.","DOI":"10.1515\/almed-2020-0038"},{"key":"2025091905582874423_j_almed-2025-0110_ref_030","doi-asserted-by":"crossref","unstructured":"Martins, I, Ribeiro, IP, Jorge, J, Gon\u00e7alves, AC, Sarmento Ribeiro, AB, Melo, JB, et al.. Liquid biopsies: applications for cancer diagnosis and monitoring. Genes 2021;12:349. https:\/\/doi.org\/10.3390\/genes12030349.","DOI":"10.3390\/genes12030349"},{"key":"2025091905582874423_j_almed-2025-0110_ref_031","doi-asserted-by":"crossref","unstructured":"Joana, HJ, Consuelo, BB. An\u00e1lisis de biopsias l\u00edquidas para el diagn\u00f3stico del c\u00e1ncer: revisi\u00f3n sistem\u00e1tica. Rev Esp Geriatr Gerontol 2020;55:343\u20139. https:\/\/doi.org\/10.1016\/j.regg.2020.08.003.","DOI":"10.1016\/j.regg.2020.08.003"},{"key":"2025091905582874423_j_almed-2025-0110_ref_032","doi-asserted-by":"crossref","unstructured":"Bonner, ER, Saoud, K, Lee, S, Panditharatna, E, Kambhampati, M, Mueller, S, et al.. Detection and monitoring of tumor associated circulating DNA in patient biofluids. J Vis Exp 2019. https:\/\/doi.org\/10.3791\/59721.","DOI":"10.3791\/59721-v"},{"key":"2025091905582874423_j_almed-2025-0110_ref_033","doi-asserted-by":"crossref","unstructured":"Masago, K, Fujita, S, Oya, Y, Takahashi, Y, Matsushita, H, Sasaki, E, et al.. Comparison between fluorimetry (qubit) and spectrophotometry (NanoDrop) in the quantification of DNA and RNA extracted from frozen and FFPE tissues from lung cancer patients: a real-world use of genomic tests. Medicina 2021;57:1375. https:\/\/doi.org\/10.3390\/medicina57121375.","DOI":"10.3390\/medicina57121375"},{"key":"2025091905582874423_j_almed-2025-0110_ref_034","doi-asserted-by":"crossref","unstructured":"Elazezy, M, Joosse, SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J 2018;16:370\u20138. https:\/\/doi.org\/10.1016\/j.csbj.2018.10.002.","DOI":"10.1016\/j.csbj.2018.10.002"},{"key":"2025091905582874423_j_almed-2025-0110_ref_035","doi-asserted-by":"crossref","unstructured":"Moreno-Manuel, A, Calabuig-Fari\u00f1as, S, Obrador-Hevia, A, Blasco, A, Fern\u00e1ndez-D\u00edaz, A, Sirera, R, et al.. dPCR application in liquid biopsies: divide and conquer. Expert Rev Mol Diagn 2021;21:3\u201315. https:\/\/doi.org\/10.1080\/14737159.2021.1860759. Epub 2020 Dec 30. PMID: 33305634.","DOI":"10.1080\/14737159.2021.1860759"},{"key":"2025091905582874423_j_almed-2025-0110_ref_036","doi-asserted-by":"crossref","unstructured":"Chen, M, Zhao, H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics 2019;13:34. https:\/\/doi.org\/10.1186\/s40246-019-0220-8. PMID: 31370908; PMCID: PMC6669976.","DOI":"10.1186\/s40246-019-0220-8"},{"key":"2025091905582874423_j_almed-2025-0110_ref_037","doi-asserted-by":"crossref","unstructured":"Poulet, G, Massias, J, Taly, V. Liquid biopsy: general concepts. Acta Cytol 2019;63:449\u201355. https:\/\/doi.org\/10.1159\/000499337. Epub 2019 May 15. PMID: 31091522.","DOI":"10.1159\/000499337"},{"key":"2025091905582874423_j_almed-2025-0110_ref_038","doi-asserted-by":"crossref","unstructured":"Pantel, K, Alix-Panabi\u00e8res, C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol 2019;16:409\u201324. https:\/\/doi.org\/10.1038\/s41571-019-0187-3. PMID: 30796368.","DOI":"10.1038\/s41571-019-0187-3"},{"key":"2025091905582874423_j_almed-2025-0110_ref_039","doi-asserted-by":"crossref","unstructured":"Ito, T, Tanaka, Y, Murata, M, Kaku-Ito, Y, Furue, K, Furue, M. BRAF heterogeneity in melanoma. Curr Treat Opt Oncol 2021;22:20. https:\/\/doi.org\/10.1007\/s11864-021-00818-3. PMID: 33558987.","DOI":"10.1007\/s11864-021-00818-3"},{"key":"2025091905582874423_j_almed-2025-0110_ref_040","doi-asserted-by":"crossref","unstructured":"Ou, SI, Nagasaka, M, Zhu, VW. Liquid biopsy to identify actionable genomic alterations. Am Soc Clin Oncol Educ Book 2018;38:978\u201397. PMID: 30231331; PMCID: PMC6865813 https:\/\/doi.org\/10.1200\/EDBK_199765.","DOI":"10.1200\/EDBK_199765"},{"key":"2025091905582874423_j_almed-2025-0110_ref_041","unstructured":"QIAGEN. Therascreen BRAF V600E kit. QIAGEN. [Acceso 7 feb 2025]. Disponible en: https:\/\/www.qiagen.com."},{"key":"2025091905582874423_j_almed-2025-0110_ref_042","unstructured":"EntroGen. BRAF mutation analysis kit. EntroGen. [Acceso 7 feb 2025]. Disponible en: https:\/\/www.entrogen.com."},{"key":"2025091905582874423_j_almed-2025-0110_ref_043","unstructured":"Biocartis. Idylla\u2122 BRAF mutation test. Biocartis. [Acceso 7 feb 2025]. Disponible en: https:\/\/www.biocartis.com."},{"key":"2025091905582874423_j_almed-2025-0110_ref_044","doi-asserted-by":"crossref","unstructured":"Wan, J, Massie, C, Garcia, CJ, Mouliere, F, Brenton, JD, Caldas, C, et al.. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17:223\u201338. https:\/\/doi.org\/10.1038\/nrc.2017.7.","DOI":"10.1038\/nrc.2017.7"},{"key":"2025091905582874423_j_almed-2025-0110_ref_045","doi-asserted-by":"crossref","unstructured":"Montealegre, PAL, Pacheco, OR, Mart\u00ednez, GH, Paniagua, F, Ardila, J, Cayol, F, et al.. La biopsia l\u00edquida en el diagn\u00f3stico y monitoreo de pacientes oncol\u00f3gicos: Oportunidades y retos en Latinoam\u00e9rica. Rev Colomb Cancerol 2020;24:151\u201364. Epub March 29, 2021.","DOI":"10.35509\/01239015.44"}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0110\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:59:32Z","timestamp":1758261572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0110\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,28]]},"published-print":{"date-parts":[[2025,9,19]]}},"alternative-id":["10.1515\/almed-2025-0110"],"URL":"https:\/\/doi.org\/10.1515\/almed-2025-0110","relation":{},"ISSN":["2628-491X"],"issn-type":[{"type":"electronic","value":"2628-491X"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}